Rights offering for $55 million
Company: Core Scientific
The claim, verbatim
Holders of pre-emergence common stock were granted rights to purchase up to $55 million of new common stock pursuant to the reorganization plan
Source (primary)
Core Scientific SC 13D/A filed 2024-02-21 (SEC EDGAR, sec_filing)
View cached copy (2026-08-31)Live source ↗
Quote: “holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the " Rights Offering ") for the purchase, on a pro rata basis, of up to $55 million of Common Stock to be issued pursuant to the Plan.”
How we checked this
Checked on September 18, 2026. The cited source supports every part of this claim.
The filing says that, under the plan, holders of Old Common Stock as of November 16, 2023 could buy up to $55 million of new common stock pro rata in a rights offering.
Confirmed in the source:
- Holders of the pre-emergence (Old) common stock were granted rights to participate in a rights offering
- The rights offering was for up to $55 million of new common stock
- The rights offering was conducted pursuant to the reorganization plan
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312524041535/d791854dsc13da.htm) in full (16,139 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific SC 13D/A filed 2024-02-21
Quote: “holders of the Issuer's Old Common Stock as of November 16, 2023 were granted the right to participate in a rights offering (the " Rights Offering ") for the purchase, on a pro rata basis, of up to $55 million of Common Stock to be issued pursuant to the Plan.”